Minor products of reaction of DNA with alpha-acetoxytamoxifen

被引:44
作者
Osborne, MR [1 ]
Hardcastle, IR [1 ]
Phillips, DH [1 ]
机构
[1] INST CANC RES,CRC,CTR CANC THERAPEUT,SUTTON SM2 5NG,SURREY,ENGLAND
关键词
D O I
10.1093/carcin/18.3.539
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The drug tamoxifen shows evidence of genotoxicity and induces liver tumours in rats, Covalent DNA adducts have been detected in the liver of rats treated with tamoxifen and these arise, at least in part, from its metabolite alpha-hydroxytamoxifen, This probably undergoes conjugation in the liver tissue to give an ester, which alkylates DNA, We have prepared alpha-acetoxytamoxifen as a model for this reactive intermediate and studied its reaction with DNA in vitro, The products of this reaction were chromatographically identical to DNA adducts found in the liver of rats treated with tamoxifen, We have isolated three of these products as the nucleosides TG1, TG2 and TA1 and identified them by ultraviolet, mass and proton magnetic resonance spectroscopy, TG1 and TG2 were tamoxifen-deoxyguanosine adducts in which the a-position of tamoxifen was linked to the amino group of guanine; TG1, (E)-4-{4-[2-(dimethylamino)ethoxy]phenyl}-3,4-diphenyl-2-(9 beta-deoxyribofuranosyl-6-oxopurin-2-ylamino)-3-butene; TG2, (Z) isomer of TG1, In TG2, the tamoxifen group had undergone trans-cis isomerization, The minor product TA1 was a tamoxifen-deoxyadenosine adduct, where linkage was through the amino group of adenine: (E)-4-{4-[2-(dimethylamino)ethoxy]phenyl}-3,4-diphenyl-2-(9 beta-deoxyribofuranosylpurin-6-ylamino)-3-butene. These three adducts accounted for > 90% of the reaction products (similar to 67% TG1, 18% TG2 and 7% TA1); trace products included other stereoisomers of these and dinucleotide adducts which resisted enzymatic digestion.
引用
收藏
页码:539 / 543
页数:5
相关论文
共 29 条
[1]  
Carmichael PL, 1996, CANCER RES, V56, P1475
[2]   POPULATION-BASED STUDY OF TAMOXIFEN THERAPY AND SUBSEQUENT OVARIAN, ENDOMETRIAL, AND BREAST CANCERS [J].
COOK, LS ;
WEISS, NS ;
SCHWARTZ, SM ;
WHITE, E ;
MCKNIGHT, B ;
MOORE, DE ;
DALING, JR .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (18) :1359-1364
[3]  
Cuenca RE, 1996, CANCER, V77, P2058, DOI 10.1002/(SICI)1097-0142(19960515)77:10<2058::AID-CNCR14>3.3.CO
[4]  
2-V
[5]   Second cancers after adjuvant tamoxifen therapy for breast cancer [J].
Curtis, RE ;
Boice, JD ;
Shriner, DA ;
Hankey, BF ;
Fraumeni, JF .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (12) :832-834
[6]  
GREAVES P, 1993, CANCER RES, V53, P3919
[7]  
HAN XL, 1992, CANCER RES, V52, P1360
[8]  
HARD GC, 1993, CANCER RES, V53, P4534
[9]  
Hemminki K, 1996, CANCER RES, V56, P4374
[10]   Conformational studies and electronic structures of tamoxifen and toremifene and their allylic carbocations proposed as reactive intermediates leading to DNA adduct formation [J].
Kuramochi, H .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (15) :2877-2886